Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820253 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2019.08.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world evidence of adjuvant immunotherapy in resected stage III and IV melanoma patients: CADIM trial final results. Experience from 2 tertiary referral centers.
Actas Dermosifiliogr
December 2024
Servicio de Oncología Médica, Hospital Clínico Universitario Virgen de la Arrixaca, Ciudad de Murcia, Spain; Instituto Murciano de Investigación Biosanitaria (IMIB), Spain.
Introduction: Clinical trials have validated the use of nivolumab and pembrolizumab as adjuvant therapies regarding relapse-free survival (RFS) in patients with resected stage III and IV melanoma. Evidence in real-world patients is currently limited.
Material And Method: The CADIM trial (Characterization of adjuvant immunotherapy in melanoma patients) recruited a total of 81 patients with resected stage III and IV melanoma on nivolumab or pembrolizumab as adjuvant therapy from February 2018 through December 2022.
ZSH-2208: A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ-TNFAIP3 axis.
Clin Transl Med
January 2025
Institute of Clinical Science, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China.
Backgroud: Oesophageal cancer ranks among the most prevalent malignant tumours globally, primarily consisting of oesophageal squamous cell carcinoma (ESCC). Cancer stem cells (CSCs) accelerate the progression ESCC via their strong self-renewal and tumourigenic capabilities, presenting significant clinical challenges due to increased risks of recurrence and drug resistance.
Methods: Our previous study has reported WYC-209, which is capable of inducing apoptosis of CSCs in melanoma and hepatoma, but is ineffective against ESCC.
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.
JAMA Oncol
December 2024
Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Importance: Progressive disease (PD) in patients treated with immune checkpoint inhibitors (ICIs) varies widely in outcomes according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Efforts to modify RECIST for ICI treatment have not resolved the heterogeneity in PD patterns, posing a clinical challenge.
View Article and Find Full Text PDFOculodermal melanocytosis in Asian Indian patients: Prevalence, clinical presentation, and association with choroidal melanoma.
Indian J Ophthalmol
January 2025
The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, Telangana, India.
Objective: To study the prevalence, clinical presentation, treatment, and follow-up of ocular (dermal) melanocytosis (ODM) and its association with choroidal melanoma (CM) in Asian Indian patients.
Methods: This was a retrospective case series of patients with ODM conducted in a quaternary eye care center.
Results: Of the total 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!